Study on the Safety and Effectiveness of Two Drug Combinations with Azacitidine for Newly Diagnosed Acute Myeloid Leukemia with IDH Mutations

Inclusion Criteria

• Have been newly diagnosed with acute myeloid leukemia (AML), either as a primary condition or as a progression from other blood disorders like myelodysplastic syndrome (MDS) or myeloproliferative neoplasms (MPN).
• Have at least 20% leukemic blasts in the bone marrow.
• Have an ECOG performance status of 0, 1, or 2, indicating full activity or some restriction in physically strenuous activity.
• Agree to undergo repeated bone marrow tests.

Exclusion Criteria

• Have or are suspected to have acute promyelocytic leukemia based on specific tests.
• Have AML that developed from chronic myelogenous leukemia (CML).
• Have previously received treatments targeting IDH1 or IDH2 mutations.
• Have or are suspected to have leukemia affecting the central nervous system (CNS). Testing for CNS involvement is only needed if there are signs of CNS leukemia during screening.